GSK PLC (GSK)
39.74
+0.48
(+1.21%)
USD |
NYSE |
Apr 19, 16:00
39.70
-0.04
(-0.11%)
After-Hours: 19:25
GSK Enterprise Value: 94.58B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 94.58B |
| April 17, 2024 | 95.26B |
| April 16, 2024 | 95.97B |
| April 15, 2024 | 97.10B |
| April 12, 2024 | 97.42B |
| April 11, 2024 | 97.71B |
| April 10, 2024 | 97.48B |
| April 09, 2024 | 97.87B |
| April 08, 2024 | 97.81B |
| April 05, 2024 | 98.51B |
| April 04, 2024 | 97.83B |
| April 03, 2024 | 99.22B |
| April 02, 2024 | 99.73B |
| April 01, 2024 | 101.02B |
| March 28, 2024 | 101.94B |
| March 27, 2024 | 102.18B |
| March 26, 2024 | 101.77B |
| March 25, 2024 | 101.86B |
| March 22, 2024 | 100.88B |
| March 21, 2024 | 100.33B |
| March 20, 2024 | 99.43B |
| March 19, 2024 | 100.22B |
| March 18, 2024 | 99.86B |
| March 15, 2024 | 99.96B |
| March 14, 2024 | 101.77B |
| Date | Value |
|---|---|
| March 13, 2024 | 102.34B |
| March 12, 2024 | 102.15B |
| March 11, 2024 | 101.44B |
| March 08, 2024 | 101.89B |
| March 07, 2024 | 102.78B |
| March 06, 2024 | 100.83B |
| March 05, 2024 | 100.79B |
| March 04, 2024 | 100.47B |
| March 01, 2024 | 99.64B |
| February 29, 2024 | 99.37B |
| February 28, 2024 | 100.26B |
| February 27, 2024 | 100.34B |
| February 26, 2024 | 100.26B |
| February 23, 2024 | 100.01B |
| February 22, 2024 | 99.89B |
| February 21, 2024 | 99.45B |
| February 20, 2024 | 99.61B |
| February 16, 2024 | 99.45B |
| February 15, 2024 | 99.10B |
| February 14, 2024 | 99.16B |
| February 13, 2024 | 98.33B |
| February 12, 2024 | 97.68B |
| February 09, 2024 | 99.39B |
| February 08, 2024 | 99.20B |
| February 07, 2024 | 99.61B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.06B
Minimum
Sep 30 2022
151.95B
Maximum
Jan 18 2022
112.87B
Average
116.32B
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 233.60B |
| Haleon PLC | 47.88B |
| Novo Nordisk A/S | 546.32B |
| Pfizer Inc | 201.80B |
| Sanofi SA | 121.93B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 434.69M |
| Revenue (Quarterly) | 10.00B |
| Total Expenses (Quarterly) | 8.544B |
| EPS Diluted (Quarterly) | 0.2111 |
| Gross Profit Margin (Quarterly) | 69.97% |
| Profit Margin (Quarterly) | 4.35% |
| Earnings Yield | 7.03% |
| Operating Earnings Yield | 10.55% |
| Normalized Earnings Yield | 7.697 |